IL178140A - Optimized expression of hpv 52 l1 gene in yeast for preparing a vaccine for treatment or prevention of hpv-associated cervical cancer - Google Patents

Optimized expression of hpv 52 l1 gene in yeast for preparing a vaccine for treatment or prevention of hpv-associated cervical cancer

Info

Publication number
IL178140A
IL178140A IL178140A IL17814006A IL178140A IL 178140 A IL178140 A IL 178140A IL 178140 A IL178140 A IL 178140A IL 17814006 A IL17814006 A IL 17814006A IL 178140 A IL178140 A IL 178140A
Authority
IL
Israel
Prior art keywords
hpv
vaccine
yeast
gene
prevention
Prior art date
Application number
IL178140A
Other languages
English (en)
Other versions
IL178140A0 (en
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL178140A0 publication Critical patent/IL178140A0/en
Publication of IL178140A publication Critical patent/IL178140A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL178140A 2004-03-24 2006-09-17 Optimized expression of hpv 52 l1 gene in yeast for preparing a vaccine for treatment or prevention of hpv-associated cervical cancer IL178140A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24
PCT/US2005/009199 WO2005097821A1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast

Publications (2)

Publication Number Publication Date
IL178140A0 IL178140A0 (en) 2006-12-31
IL178140A true IL178140A (en) 2010-11-30

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178140A IL178140A (en) 2004-03-24 2006-09-17 Optimized expression of hpv 52 l1 gene in yeast for preparing a vaccine for treatment or prevention of hpv-associated cervical cancer

Country Status (31)

Country Link
US (2) US7700103B2 (enExample)
EP (1) EP1730175B1 (enExample)
JP (1) JP4833962B2 (enExample)
KR (1) KR101203403B1 (enExample)
CN (1) CN1934131B (enExample)
AR (1) AR048191A1 (enExample)
AT (1) ATE466022T1 (enExample)
AU (1) AU2005230907C1 (enExample)
BE (1) BE2015C066I2 (enExample)
BR (1) BRPI0509079B8 (enExample)
CA (1) CA2560487C (enExample)
CY (2) CY1110349T1 (enExample)
DE (1) DE602005020913D1 (enExample)
DK (1) DK1730175T3 (enExample)
ES (1) ES2343255T3 (enExample)
FR (1) FR15C0085I2 (enExample)
HU (1) HUS1500062I1 (enExample)
IL (1) IL178140A (enExample)
LT (2) LTC1730175I2 (enExample)
LU (1) LU92903I2 (enExample)
MY (1) MY148656A (enExample)
NL (1) NL300777I2 (enExample)
NO (3) NO338055B1 (enExample)
NZ (1) NZ549898A (enExample)
PL (1) PL1730175T3 (enExample)
PT (1) PT1730175E (enExample)
RU (1) RU2373219C2 (enExample)
SI (1) SI1730175T1 (enExample)
TW (1) TWI349036B (enExample)
WO (1) WO2005097821A1 (enExample)
ZA (1) ZA200607575B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
EP2129394B1 (en) 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
MY162658A (en) 2007-11-23 2017-06-30 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
MX375965B (es) * 2010-05-14 2025-03-07 Baxalta Inc Genes ospa quimericos, proteinas, y metodos para usar los mismos.
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN102268076B (zh) * 2010-07-02 2017-04-26 厦门大学 截短的人乳头瘤病毒52型l1蛋白
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
CN103562392B (zh) 2010-12-03 2016-07-20 Ms技术有限责任公司 植物细胞中草甘膦抗性编码核酸分子的优化表达
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
TW202140069A (zh) 2020-02-14 2021-11-01 美商默沙東藥廠 Hpv疫苗
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
AR126813A1 (es) 2021-08-19 2023-11-15 Merck Sharp & Dohme Llc Nueva nanopartícula lipídica termostable y métodos de uso de la misma
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
ATE342916T1 (de) 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
ES2275350T3 (es) 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
PT1105466E (pt) * 1998-08-14 2006-07-31 Merck & Co Inc Processo para a purificacao de particulas tipo virus do papilomavirus humano
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
JP2004504057A (ja) 2000-07-21 2004-02-12 グラクソ　グループ　リミテッド コドン最適化されたパピローマウイルス配列
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
MXPA05010285A (es) 2003-03-24 2005-11-17 Merck & Co Inc Expresion optimizada de hpv 31 l1 en levadura.
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
US20080226660A1 (en) 2008-09-18
ES2343255T3 (es) 2010-07-27
NO2017005I1 (no) 2017-01-20
DK1730175T3 (da) 2010-08-23
RU2006137363A (ru) 2008-04-27
NO2022050I1 (no) 2022-11-30
PT1730175E (pt) 2010-06-25
LTPA2015050I1 (lt) 2016-01-11
EP1730175A1 (en) 2006-12-13
LTC1730175I2 (lt) 2017-05-10
CN1934131A (zh) 2007-03-21
ZA200607575B (en) 2008-08-27
CY2015052I2 (el) 2016-06-22
KR101203403B1 (ko) 2012-11-21
NO20064815L (no) 2006-10-23
AU2005230907B2 (en) 2011-05-19
LU92903I2 (fr) 2016-03-08
NO338055B1 (no) 2016-07-25
RU2373219C2 (ru) 2009-11-20
NL300777I1 (enExample) 2015-12-29
TW200602490A (en) 2006-01-16
US7744892B2 (en) 2010-06-29
KR20060134120A (ko) 2006-12-27
CA2560487C (en) 2013-01-29
EP1730175B1 (en) 2010-04-28
CN1934131B (zh) 2010-12-29
MY148656A (en) 2013-05-15
AU2005230907A1 (en) 2005-10-20
BRPI0509079B8 (pt) 2021-07-06
US20100035818A1 (en) 2010-02-11
BRPI0509079A (pt) 2007-08-21
AR048191A1 (es) 2006-04-05
IL178140A0 (en) 2006-12-31
SI1730175T1 (sl) 2010-08-31
BE2015C066I2 (enExample) 2024-08-08
PL1730175T3 (pl) 2010-09-30
CY2015052I1 (el) 2016-06-22
FR15C0085I1 (enExample) 2016-08-01
CY1110349T1 (el) 2015-04-29
WO2005097821A1 (en) 2005-10-20
JP4833962B2 (ja) 2011-12-07
BRPI0509079B1 (pt) 2020-05-19
ATE466022T1 (de) 2010-05-15
DE602005020913D1 (de) 2010-06-10
AU2005230907C1 (en) 2016-07-28
CA2560487A1 (en) 2005-10-20
US7700103B2 (en) 2010-04-20
NZ549898A (en) 2009-06-26
NL300777I2 (enExample) 2015-12-29
FR15C0085I2 (fr) 2016-11-25
TWI349036B (en) 2011-09-21
JP2007530040A (ja) 2007-11-01
HUS1500062I1 (hu) 2017-07-28

Similar Documents

Publication Publication Date Title
IL178140A (en) Optimized expression of hpv 52 l1 gene in yeast for preparing a vaccine for treatment or prevention of hpv-associated cervical cancer
HUS1500064I1 (hu) HPV58 L1 optimalizált expressziója élesztõben
HUS1500063I1 (hu) HPV 45 L1 optimalizált expresszáltatása élesztõben
PT1572095E (pt) Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
IL158107A0 (en) Human papillomaviruses vaccine
EP1948232A4 (en) VIRAL GENE PRODUCTS AND METHOD FOR THE PROTECTION AGAINST VIRUS DISEASES
AU2003272106A1 (en) Cupping moxa utensil as a herb medical auxiliary
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
GB0408978D0 (en) Meningococcal fermentation for preparing conjugate vaccines
AU2003289631A1 (en) A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof
LU92900I2 (fr) Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
PL2366400T3 (pl) Sposób leczenia pacjentów szczepionką na bazie glikoproteiny mucynowej (MUC-1)
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
GB0423681D0 (en) Vaccine and nucleic acids
EP2012829A4 (en) PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
GB2430370B (en) Chinese medicine preparation for treating AIDS
AU2003222378A8 (en) Combined dna vaccine and biological modifiers for cancer therapy
AU2003273035A1 (en) Gene vaccine
AU2003229346A1 (en) Use of a vaccine for active immunization against cancer
AU2002236065A1 (en) Papillomavirus vaccines
AU2003228816A8 (en) Production of papillomavirus vaccines in plants
AU2003243215A1 (en) Treatment for human papillomavirus
HK1102911A (en) Lipid-extracted therapeutic vaccine and method of use
AU2002321559A1 (en) Oligonucleotides for use in detection of human papillomavirus e7 mrna

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed